GLP-1 medications like semaglutide and tirzepatide are producing results that were unimaginable a decade ago. Average weight loss of 15–22%. Cardiovascular benefits confirmed in landmark trials. New FDA-approved indications piling up quarterly.
And yet, roughly half the people who start these medications stop taking them within a year. That disconnect between how well these drugs work and how many people actually stick with them is one of the most important—and under-discussed—stories in modern medicine.
The Key Numbers
A 2023 analysis of pharmacy claims data found that approximately 50% of patients prescribed a GLP-1 for weight loss discontinued within 12 months. Among those who stopped, the majority regained two-thirds of lost weight within a year of cessation.
Why So Many People Stop
Adherence isn’t a willpower issue. When you look at the data, the reasons people stop fall into a handful of predictable categories—most of which are solvable.
1. Cost and Insurance Barriers
This is the single biggest driver of discontinuation. Brand-name GLP-1s can cost $1,000–$1,500 per month without insurance. Even with coverage, prior authorization hurdles, step therapy requirements, and high copays push patients out.
When insurance changes—new employer, new plan year, new formulary—patients who were covered can suddenly find themselves paying full price. Many simply can’t absorb that financial shock.
2. Side Effects During Titration
GLP-1 medications require a gradual dose increase (titration) to reach therapeutic levels. During this process, side effects like nausea, vomiting, and diarrhea can be significant. Up to 44% of patients in clinical trials reported nausea at some point during treatment.
The critical period is weeks 4–8, when many patients are on their second or third dose increase. This is when side effects often peak—and when many patients decide the medication “isn’t for them.”
What Helps: Slower Titration
Many providers now use a slower-than-standard titration schedule—increasing doses every 6–8 weeks instead of every 4. Compounded medications offer additional flexibility since doses can be customized in smaller increments, which often reduces side effects significantly.
3. The Plateau Problem
Most patients experience rapid weight loss in the first 3–6 months, then hit a plateau. When the scale stops moving despite continued injections, motivation drops. Some patients interpret the plateau as the medication “not working anymore”—when in reality, maintaining significant weight loss is exactly what the medication is doing.
4. Supply Chain Issues
The semaglutide shortage that ended in February 2025 and the tirzepatide shortage that ended in October 2024 created months of disruption. Patients who couldn’t get their medication for weeks at a time often lost momentum—and the restart process (re-titrating from a lower dose) discouraged many from continuing.
5. Unrealistic Expectations
Social media has created an expectation of rapid, dramatic transformation. When a patient loses 8% of their body weight in 6 months—a clinically excellent result—but expected 20%, they may feel the medication has failed.
What the Research Says About Successful Adherence
Patients who stay on GLP-1 therapy long-term tend to share several characteristics:
- Affordable access: Whether through insurance, manufacturer programs, or compounded alternatives, financial sustainability is the top predictor of adherence
- Provider communication: Patients who have regular check-ins with their prescribing provider are more likely to persist through side effects and plateaus
- Realistic goal-setting: Understanding that 10–15% weight loss is a strong clinical outcome helps patients stay motivated
- Side effect management: Proactive strategies (smaller meals, hydration, anti-nausea support) improve tolerability
- Lifestyle integration: Patients who pair medication with strength training and protein-focused nutrition report higher satisfaction and better outcomes
The Cost Factor: Where Compounded Options Fit
If cost is the number-one reason people stop, then affordable alternatives are the number-one solution. Compounded semaglutide and tirzepatide—available through licensed 503A and 503B pharmacies—can reduce monthly costs to $150–$400, compared to $1,000+ for brand-name versions.
This price difference isn’t marginal. For many patients, it’s the difference between 6 months of treatment and 6 years. And the data is clear: longer treatment duration correlates with better long-term outcomes.
Long-Term Thinking
Obesity is a chronic condition. Treating it with a 6-month course of medication is like treating high blood pressure with a 6-month course of medication—it works while you take it. The goal should be sustainable, long-term access at a price you can maintain.
Practical Strategies to Stay on Track
Build a Side-Effect Toolkit Early
Don’t wait until nausea hits to develop a plan. From day one, eat smaller portions, prioritize protein, stay hydrated, and keep bland snacks (crackers, toast) available. Talk to your provider about anti-nausea options if symptoms are disrupting daily life.
Set Non-Scale Goals
Track measurements, energy levels, sleep quality, lab values (A1C, blood pressure, cholesterol), and how your clothes fit. Weight is only one metric—and often not the most meaningful one.
Plan for the Financial Long Haul
If you’re using insurance, understand your plan’s formulary and prior authorization requirements. Know when your plan year resets and whether your coverage could change. If you’re paying out of pocket, explore compounded options that fit a sustainable monthly budget.
Don’t Skip Appointments
Regular check-ins with your provider help catch issues early. If side effects are becoming intolerable, your provider can adjust your dose, switch medications, or add supportive treatments. Going silent and quitting is the worst-case scenario.
The Bottom Line
The 50% dropout rate isn’t evidence that GLP-1s don’t work. They work remarkably well. It’s evidence that the healthcare system hasn’t yet solved for access, affordability, and long-term support. As costs come down through compounding, generic competition (Canadian generic semaglutide launches in 2026), and eventual U.S. generics, adherence should improve.
In the meantime, the best thing you can do is plan for the long term from day one. This isn’t a quick fix—it’s a treatment for a chronic condition. Treat it that way, and you’re far more likely to be in the half that stays.